Home>Topics>Companies>Forest Laboratories

Forest Laboratories FRX

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. U.S. allows Actavis Plc's purchase of Forest Labs with conditions


      Mon, 30 Jun 2014

      WASHINGTON, June 30 (Reuters) - Pharmaceutical company Actavis Plc has won U.S. approval to buy Forest Laboratories on condition that it sell or relinquish the rights to four generic medicines, the Federal Trade Commission said on Monday.

    2. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns


      Thu, 26 Jun 2014

      4.0 times pro forma EBITDA from an estimated 3.6 times at the end of 2013 in order to fund its purchase of Forest Laboratories FRX "> FRX . As such, we downgraded our credit rating for Actavis to BBB from BBB+. Mallinckrodt MNK "> MNK

    3. Forest antidepressant Viibryd succeeds in anxiety disorder trials


      Mon, 23 Jun 2014

      June 23 (Reuters) - Forest Laboratories Inc, which is being acquired by generic drugmaker Actavis Plc, said on Monday that its antidepressant Viibryd performed significantly better than a placebo for...

    4. Top Holdings of Four All-Weather Ultimate Stock-Pickers


      Tue, 17 Jun 2014

      is still beating the market overall. The fund's best-performing stock during the first quarter of 2014 was Forest Laboratories FRX, which was up 54% during the period following a $25 billion takeover bid from Actavis ACT. The stock was

    5. Actavis Posts Strong Results as Integration with Forest Labs Approaches


      Wed, 30 Apr 2014

      driven largely by the integration of Warner Chilcott, and earnings have mostly tracked our forecast. Assuming the Forest Laboratories deal closes near the middle of this year, we still think Actavis will post more than $12.5 billion in revenue for

    6. Sell-Off in Health Care Sector Overlooks Strong Fundamentals


      Fri, 25 Apr 2014

      Investor interest in recent tax-advantaged deals has been undeniable. As we saw in Actavis’ acquisition of Forest Laboratories , both the acquirer’s and the acquisition target’s stocks rose after the deal announcement as investors

    7. New Morningstar Analyst Report for Actavis PLC

      Stock Reports

      Wed, 12 Mar 2014

      value estimate for Actavis to $200 per share from $168 after incorporating potential synergies from the announced Forest Laboratories acquisition. As long as management can achieve its $1 billion cost synergy target, the deal should push annual free cash

    8. M&A: A New Rx for Specialty Pharma


      Mon, 10 Mar 2014

      aligned with shareholders. At Forest Laboratories , for example, the new CEO put ..... Ireland. Likewise, Actavis and Forest Laboratories were up 17% and 39%, respectively ..... February it would acquire Forest Laboratories . The secular trends favoring

    9. New Morningstar Analyst Report for Forest Laboratories , Inc.

      Stock Reports

      Wed, 8 Jan 2014

      been put to to work for shareholders returning hundreds of millions of dollars per year in additional earnings. Forest Laboratories is a pharmaceutical company focused on in-licensing drugs for development. The company's portfolio includes

    10. Forest Labs' longtime CEO Solomon to step down at year-end


      Thu, 23 May 2013

      May 23 (Reuters) - Forest Laboratories Inc said on Thursday that Howard Solomon, who has led the biotech firm since 1977, will retire as chief executive officer at the end of this year and the...

    « Prev12345Next »
    Content Partners